Ratings Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
34.84 ^USD	+0.20%		-2.44%	+13.19%

Apr. 11	Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	MT
Feb. 26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company's attractive earnings multiples are brought to light by a P/E ratio at 11.78 for the current year.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the past four months, analysts' average price target has been revised upwards significantly.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
COLLEGIUM PHARMACEUTICAL, INC.	+13.19%	1.14B	C+
ELI LILLY AND COMPANY	+24.60%	672B	C+
NOVO NORDISK A/S	+24.08%	550B	B
JOHNSON & JOHNSON	-5.63%	351B	C+
MERCK & CO., INC.	+15.37%	317B	B-
ABBVIE INC.	+7.38%	292B	C+
ASTRAZENECA PLC	+3.26%	211B	B+
NOVARTIS AG	+0.78%	203B	B-
PFIZER, INC.	-9.69%	144B	C+
AMGEN INC.	-6.63%	141B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes